Greek Syriza leader says Greece's bailout pledges are null and void after the vote
Green Mtn Coffee Chairman discloses sale of 5.0 mln shares on 5/7, worth $125.5 mln, pursuant to margin sell-out - SEC 144 filing.
Sellest siis ka eilne aktsia nõrkus.
Sellest siis ka eilne aktsia nõrkus.
Jaemüüjad on endiselt nõrga Euroopa tõttu tule all ja täna on oma osa saamas Fossil (FOSL), mis kaupleb eelturul tulemustejärgselt 25% miinuspoolel $ 94,00 taseme kandis.
Firma andis teiseks kvartaliks konsensuse ootustest nõrgema prognoosi ja äritegevust pidurdab just Euroopa, sest nii Aasias kui ka Põhja-Ameerikas on müük jätkuvalt tugev.
Firma andis teiseks kvartaliks konsensuse ootustest nõrgema prognoosi ja äritegevust pidurdab just Euroopa, sest nii Aasias kui ka Põhja-Ameerikas on müük jätkuvalt tugev.
Eile tuli tulemustega ka Dendreon (DNDN):
Reports Q1 (Mar) adjusted loss of $0.35 per share, $0.24 better than the Capital IQ Consensus Estimate of ($0.59); revenues rose 204.1% year/year to $82.1 mln vs the $81.54 mln consensus.
Siin ka mõned analüütikute kommentaarid:
•Cantor notes DNDN reported 1Q:12 EPS (excluding $0.11 related to separation costs) of ($0.59) per share vs. ($0.77) in the prior year and our forecast of ($0.61). More importantly, however, was revenue, which came in at $82 million, a 6.6% increase vs. 4Q:11 and in line with firm's forecast. Though a number of measures showed improvement in the quarter, including a 94 bps sequential rise in gross margin, the guidance of modest quarter-on-quarter growth may come across as a disappointment. Firm believes the conservative guidance is appropriate given the numerous factors at play for Provenge but visibility on improving financials is still somewhat muddled.
•Brean Murray notes gross to net sales reduction is now up to 7.5% and is expected to remain at that level for the time being. COGS were $60 million (73.2% of net sales), which firm views as still unimpressively high seven quarters after launch. COGS should remain high going forward, and this year has started including the cost of antigen, which for sales through 2011 was already booked pre-commercially as R&D years ago. Firm continues to believe that COGS are the largest obstacle to being cash flow positive, let alone profitable. Firm is confident that DNDN will not be profitable until 2015 at the earliest.
Leerink Swann alandab DNDN reitingu täna Osta pealt Hoia peale.
Aktsia kaupleb eelturul 13.7% miinuspoolel, $ 10 taseme juures.
Reports Q1 (Mar) adjusted loss of $0.35 per share, $0.24 better than the Capital IQ Consensus Estimate of ($0.59); revenues rose 204.1% year/year to $82.1 mln vs the $81.54 mln consensus.
Siin ka mõned analüütikute kommentaarid:
•Cantor notes DNDN reported 1Q:12 EPS (excluding $0.11 related to separation costs) of ($0.59) per share vs. ($0.77) in the prior year and our forecast of ($0.61). More importantly, however, was revenue, which came in at $82 million, a 6.6% increase vs. 4Q:11 and in line with firm's forecast. Though a number of measures showed improvement in the quarter, including a 94 bps sequential rise in gross margin, the guidance of modest quarter-on-quarter growth may come across as a disappointment. Firm believes the conservative guidance is appropriate given the numerous factors at play for Provenge but visibility on improving financials is still somewhat muddled.
•Brean Murray notes gross to net sales reduction is now up to 7.5% and is expected to remain at that level for the time being. COGS were $60 million (73.2% of net sales), which firm views as still unimpressively high seven quarters after launch. COGS should remain high going forward, and this year has started including the cost of antigen, which for sales through 2011 was already booked pre-commercially as R&D years ago. Firm continues to believe that COGS are the largest obstacle to being cash flow positive, let alone profitable. Firm is confident that DNDN will not be profitable until 2015 at the earliest.
Leerink Swann alandab DNDN reitingu täna Osta pealt Hoia peale.
Aktsia kaupleb eelturul 13.7% miinuspoolel, $ 10 taseme juures.
The Washington Times kirjutab, et esialgsete andmete kohaselt oli aprillikuu Obama administratsiooni jaoks esimene eelarve ülejäägiga kuu.
The numbers, compiled by the Congressional Budget Office, mark the first monthly surplus under President Obama, who when he took office in January 2009 began a program of boosted spending and continued tax cuts to try to bolster the foundering economy, but saw those efforts splash red ink across the federal budget.
Boosted by better tax collections and slightly slower spending, the government recorded a $58 billion surplus in April. That’s nearly a $100 billion turnaround from April 2011, when the government ran a $40 billion deficit.
The numbers suggest that the government’s short-term fiscal picture has improved slightly since the deepest days of the recession, when stimulus spending and tax cuts spilled red ink over the federal budget.
“Because of the large inflows of tax revenues, the federal government usually runs a budget surplus in April — though that did not occur in 2009, 2010 and 2011,” CBO said.
FL Foot Locker: Hearing Buckingham out intraday on FL; believes sell off is a buying opportunity
FL kaupleb hetkel 4% miinuspoolel
FL kaupleb hetkel 4% miinuspoolel
Fossil: Hearing Piper defending FOSL; leaves rating at Overweight, lowers tgt to $132 from $138
RBCN Rubicon Tech reports EPS in-line, beats on revs; guides Q2 EPS in-line, revs in-line (8.95 -0.13)
Reports Q1 (Mar) loss of $0.15 per share, in-line with the Capital IQ Consensus Estimate consensus of ($0.15); revenues fell 73.2% year/year to $10.2 mln vs the $10.03 mln consensus. Co issues in-line guidance for Q2, sees EPS of ($0.10)-(0.14) vs. ($0.12) Capital IQ Consensus Estimate; sees Q2 revs of $15-18 mln vs. $16.22 mln Capital IQ Consensus Estimate.
Reports Q1 (Mar) loss of $0.15 per share, in-line with the Capital IQ Consensus Estimate consensus of ($0.15); revenues fell 73.2% year/year to $10.2 mln vs the $10.03 mln consensus. Co issues in-line guidance for Q2, sees EPS of ($0.10)-(0.14) vs. ($0.12) Capital IQ Consensus Estimate; sees Q2 revs of $15-18 mln vs. $16.22 mln Capital IQ Consensus Estimate.